Success Metrics

Clinical Success Rate
94.1%

Based on 16 completed trials

Completion Rate
94%(16/17)
Active Trials
4(18%)
Results Posted
31%(5 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_1
1
5%
Ph phase_2
8
36%
Ph phase_3
6
27%
Ph not_applicable
2
9%
Ph phase_4
4
18%

Phase Distribution

1

Early Stage

8

Mid Stage

10

Late Stage

Phase Distribution21 total trials
Phase 1Safety & dosage
1(4.8%)
Phase 2Efficacy & side effects
8(38.1%)
Phase 3Large-scale testing
6(28.6%)
Phase 4Post-market surveillance
4(19.0%)
N/ANon-phased studies
2(9.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

94.1%

16 of 17 finished

Non-Completion Rate

5.9%

1 ended early

Currently Active

4

trials recruiting

Total Trials

22

all time

Status Distribution
Active(4)
Completed(16)
Terminated(1)
Other(1)

Detailed Status

Completed16
Recruiting4
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
22
Active
4
Success Rate
94.1%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (4.8%)
Phase 28 (38.1%)
Phase 36 (28.6%)
Phase 44 (19.0%)
N/A2 (9.5%)

Trials by Status

recruiting418%
terminated15%
unknown15%
completed1673%

Recent Activity

Clinical Trials (22)

Showing 20 of 22 trialsScroll for more
NCT07242092Phase 4

Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs

Recruiting
NCT07135453Phase 4

Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

Recruiting
NCT07460154Not Applicable

Structured Review: To Optimise Management and Prevent Harm in COPD

Recruiting
NCT07252791Phase 4

Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases

Recruiting
NCT05788510

Pneumococcal Vaccination in Patients with Anti-TNF Alpha Therapy

Completed
NCT06202703Not Applicable

Fine Needle aSpiration of Lymph nodEs to Study vAccine-induced Immunity

Unknown
NCT04515147Phase 2

A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19

Completed
NCT01411241Phase 3

Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers

Completed
NCT00307541Phase 3

Assess the Immunogenicity of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Completed
NCT00169507Phase 3

Study of Immunological Memory Induced in Children by a Full 4 Dose Vaccination Schedule of 11 Valent Pneumococcal Conjugate Vaccine by Giving 1 Dose of Aventis Pasteur's 23-valent Pneumococcal Polysaccharide Vaccine (Pneumo 23)

Completed
NCT00169481Phase 2

A Study in Children With Different Formulations of GSK Biologicals' 11 Valent Pneumococcal Conjugate Vaccine

Completed
NCT00334334Phase 3

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

Completed
NCT00333450Phase 3

Immune Memory Evaluation in Children Following a Primary Vaccination With Pneumococcal Conjugate Vaccines.

Completed
NCT00338351Phase 2

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine.

Completed
NCT00307554Phase 3

A Lot-to-lot Consistency (3 Lots of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine) & Non-inferiority Study

Completed
NCT00307567Phase 2

Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488

Completed
NCT01339000Phase 2

Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy

Terminated
NCT00239694Phase 4

PPV: Pneumococcal Polysaccharide Vaccine in Older Adults

Completed
NCT00721396Phase 2

Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules

Completed
NCT00323557Phase 2

Immuno-Augmentation With GM-CSF of Pneumococcal Vaccine in Chronic Lymphocytic Leukemia Patients

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
22